Back to Search
Start Over
Advances in amyloid-targeting monoclonal antibodies for Alzheimer's disease: clinical and public health issues.
- Source :
- Expert Review of Neurotherapeutics; 2023, Vol. 23 Issue 12, p1113-1129, 17p
- Publication Year :
- 2023
-
Abstract
- Alzheimer's disease (AD) is a major global public health challenge. To date, no treatments have been shown to stop the underlying pathological processes. The cerebral accumulation of amyloid-beta (Ab) is still considered as the primum movens of AD and disease-modifying treatments targeting Ab are reaching – or have already reached – clinical practice. The authors explore the main advancements from Aβ-targeting monoclonal antibodies (mAbs) for the treatment of AD. From a public health perspective, they address ethically relevant issues such as the benevolence and non-maleficence principles. They report on the potential biological and clinical benefits of these drugs, discussing minimal clinically important differences (MCID) and other relevant outcomes. They examine the short- and long-term effects of amyloid-related imaging abnormalities (ARIA), and explore the differences between eligibility criteria in clinical trials, appropriate use recommendations, and prescribing information content. In doing so, they contextualize the discussion on the disagreements among different regulatory authorities. Although anti-β-amyloid monoclonal antibodies may be effective in selected scenarios, non-negligible knowledge gaps and implementation limits persist. Overcoming these gaps can no longer be postponed if we are to ensure the principles of Quality of Care for patients with cognitive impairment who would be eligible for this class of drugs. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14737175
- Volume :
- 23
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- Expert Review of Neurotherapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 174275888
- Full Text :
- https://doi.org/10.1080/14737175.2023.2284305